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Abstract: Doxorubicin (DOX) is a very potent and effective anticancer agent. However, the effectiveness
of DOX in osteosarcoma is usually limited by the acquired drug resistance. Recently, Vitamin D (Vit-D)
was shown to suppress the growth of many human cancer cells. Taken together, we synthesized DOX-Vit
D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate
the chemoresistance associated with DOX. For this purpose, MG63 cells were treated with 10 µM DOX
or DOX-Vit D for 24 h. Thereafter, MTT, real-time PCR and western blot analysis were used to determine
cell proliferation, genes and proteins expression, respectively. Our results showed that DOX-Vit D,
but not DOX, significantly elicited an apoptotic signal in MG63 cells as evidenced by induction of
death receptor, Caspase-3 and BCLxs genes. Mechanistically, the DOX-Vit D-induced apoptogens were
credited to the activation of p-JNK and p-p38 signaling pathway and the inhibition of proliferative
proteins, p-Akt and p-mTOR. Our findings propose that DOX-Vit D suppressed the growth of MG63
cells by inducing apoptosis while inhibiting cell survival and proliferative signaling pathways. DOX-Vit
D may serve as a novel drug delivery approach to potentiate the delivery of DOX into cancer cells.
Keywords: doxorubicin; MG63; Vitamin D; DOX-Vit D
1. Introduction
Osteosarcoma (OS) is one of the most widespread and lethal forms of childhood primary bone
cancer [1]. In Canada, OS accounts for about 5% of all tumors in pediatric patients with an incidence
rate of 8 cases per million each year especially in adolescents [2,3]. Despite the substantial progress in
chemotherapies against OS, the mortality rate of OS patients has not been changed significantly due to
chemoresistance and other factors [4].
One of those standard therapies for OS is doxorubicin (DOX), an effective anthracycline
antibiotic [5]. The combination of DOX with other chemotherapeutic agents such as cisplatin, ifosfamide
and methotrexate cured 60–76% of newly diagnosed non-metastatic OS [6]. Although DOX has
improved survival rates in cancer patients, the effectiveness of DOX in OS is usually limited by
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the acquired drug resistance. This resistance is dose-dependent and may develop gradually within
a month or years after the treatment initiation. Though the specific mechanism of chemoresistance
associated with DOX is still unclear, several reports have demonstrated that drug inactivation, increased
DNA damage repair, disturbances in intracellular drug transport and evasion of apoptosis could play a
role in the chemoresistance [7].
Numerous epidemiological reports have suggested a strong association between Vitamin D (Vit-D)
and cancer risk [8,9]. The deficiency of Vit-D has been reported to contribute to the development of
tumors whereas, higher intake of Vit-D was accompanied by a lower incidence of cancer disease [10,11].
Experimental studies using cancer cells or tumors in mice have shown that Vit-D exhibited antitumor
activities through the induction apoptosis in addition to the inhibition of cell proliferation and
differentiation [12,13].
Vit-D can be classified naturally into animal-based Vit-D3 and plant-based Vitamin D2. Vit-D3,
cholecalciferol, is synthesized by the mammalian skin after exposure to sunlight then metabolized into
its active form, calcitriol, in the liver and kidneys [14]. Upon binding to its receptor, calcitriol activates
several signaling pathways that regulate bone metabolism and calcium homeostasis. Of interest,
calcitriol was shown to inhibit the growth, proliferation and differentiation of many cancer cell lines
such as breast, prostate and colon cancers [15,16]. However, the anticancer activity of calcitriol
was associated with significant hypercalcemia that limits its clinical utility [17]. In contrast to
Vit-D3, ergocalciferol, Vit-D2, has been reported to exert a low calcemic effect and potent antitumor
activity [14,18]. Ergocalciferol, Vit-D2, occurs naturally in plants and it is synthesized from proVit-D2,
ergosterol, upon exposure to sunlight [14]. Of particular interest, it has been reported that Vit-D2
enhanced the cytotoxic effect of DOX on human breast and prostate cancer cell lines [19].
In light of the information described above, we hypothesized that by synthesis of DOX-Vit D, a novel
DOX derivative, through conjugating Vit-D2 to DOX, the chemoresistance associated with DOX could
be mitigated. For this purpose, the current study was designed to (1) investigate the antiproliferative
and apoptogenic effects of DOX-Vit D in the human OS cell line, MG63 cells, and (2) explore the possible
mechanism(s) involved. Our study provides substantial evidence that DOX-Vit D suppressed the growth
of MG63 cells by inducing apoptosis while inhibiting cell survival and proliferative signaling pathways.
Our DOX-Vit D conjugate may be of particular importance in drug delivery and may serve as a novel
drug delivery approach to potentiate the delivery of DOX into the bone cancer cells.
2. Materials and Methods
2.1. Materials
Total Akt (t-Akt) rabbit polyclonal, phosphorylated-Akt (P-Akt) rabbit polyclonal, mammalian
target of rapamycin C (t-mTOR) goat polyclonal and p-mTOR rabbit polyclonal were bought from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Any other materials used in the current study
has been described previously [20].
2.2. Chemistry
2.2.1. Calciferol-Succinate
In a round bottom flask, 200 mg of calciferol (0.5 mmol) was dissolved in 20 mL of anhydrous
dichloromethane (DCM), followed by the addition of 360 mg of succinic anhydride (3.6 mmol, 7.2 eq.)
and 500 µL of triethylamine (TEA, 3.6 mmol, 7.2 eq.). The reaction mixture was stirred at ambient
temperature under N2 for 24 h in the dark. The solution was washed with water three times, and
the organic layer was concentrated under reduced pressure. The compound was purified with a
Combiflash RF system (hexane/ethyl acetate, 30/70) to obtain a yellowish solid with a yield of 93%.
1H NMR (400 MHz, Acetone-d6) δ 6.30 (d, J = 11.2 Hz, 1H), 6.10 (dt, J = 11.3, 1.6 Hz, 1H), 5.35–5.18 (m,
2H), 5.12 (dt, J = 2.6, 1.2 Hz, 1H), 4.94 (tt, J = 7.8, 3.8 Hz, 1H), 4.84 (d, J = 2.6 Hz, 1H), 4.07 (q, J = 7.1 Hz,
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1H), 2.90 (dd, J = 11.9, 4.0 Hz, 1H), 2.69–2.50 (m, 5H), 2.49–2.32 (m, 2H), 2.27–2.16 (m, 1H), 2.16–1.94 (m,
6H), 1.89 (qd, J = 6.9, 5.9 Hz, 1H), 1.83–1.65 (m, 4H), 1.66–1.27 (m, 7H), 1.22 (t, J = 7.1 Hz, 1H), 1.07 (d,
J = 6.7 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H), 0.87 (t, J = 6.6 Hz, 6H) (Figures 1 and 2).
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2.2.2. Calciferol-Succinate-DOX
Calciferol-succinate (230 mg, 0.463 mmol), HATU, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluor phosphate (HATU) (211 mg, 1.2 eq.), and Dox-HCl (295 mg.
1.1 eq.) were di solv in 10 mL of anhydrous N,N-Dimethylformamide (DMF). T the he mixture was
added 400 µL of N,N-Diisopropylethylamine (DIPEA) solution was stirred at ambient temperature
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under N2 for 24 h in the dark. The crude mixture was dried under reduced pressure, and purified with
a Combiflash RF system (hexane/ethyl acetate, 50/50) to afford product as an orange solid with a yield
of 60%. 1H NMR (400 MHz, Acetone-d6) δ 8.68 (dd, J = 4.4, 1.4 Hz, 1H), 8.50–8.37 (m, 1H), 7.56–7.38
(m, 1H), 6.14 (d, J = 11.2 Hz, 1H), 5.94 (dd, J = 11.2, 1.8 Hz, 1H), 5.23–5.05 (m, 2H), 4.97 (dq, J = 3.6,
2.2, 1.8 Hz, 1H), 4.86 (tt, J = 7.7, 3.8 Hz, 1H), 4.69 (d, J = 2.7 Hz, 1H), 3.22–3.09 (m, 2H), 2.84–2.71 (m,
2H), 2.71–2.63 (m, 1H), 2.54–2.39 (m, 2H), 2.37–2.24 (m, 2H), 2.08 (dddd, J = 12.3, 5.9, 4.7, 3.5 Hz, 2H),
1.98–1.79 (m, 8H), 1.78–1.55 (m, 4H), 1.55–1.42 (m, 3H), 1.42–1.10 (m, 9H), 0.95–0.86 (m, 4H), 0.80 (d,
J = 6.8 Hz, 4H), 0.72 (t, J = 6.7 Hz, 7H). ESI (m/z); calculated for C59H79N2O14 [M + NH4]+: 1039.5531;
found: 1039.7386 (Figures 1 and 2).
2.3. Cell Culture and Treatments
The human osteosarcoma cancer cell line, MG63 cells, (ATCC, Manassas, VA, USA) was
maintained according to the ATCC’s instructions.
2.4. Effect of DOX and DOX-Vit D on MG63 Cell Proliferation
The effect of DOX and DOX-Vit D on MG63 cell proliferation was determined by measuring the
capacity of reducing enzymes to convert 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide
(MTT) to colored formazan crystals as described previously [21,22]. The percentage of cell proliferation
was calculated relative to control wells designated as 100% viable cells using the following formula:
cell proliferation = (Atreated)/(Acontrol)× 100% (1)
2.5. RNA Extraction and cDNA Synthesis
Total RNA was extracted using TRIzol reagent (Invitrogen®, Carlsbad, CA, USA) as described
previously [20].
2.6. Quantification of mRNA Expression by Quantitative Real-Time Polymerase Chain Reaction (Real
Time-PCR)
Quantification of specific gene expression was performed by real time-PCR using ABI Prism 7500
System (Applied Biosystems, Foster City, CA, USA) as previously described [23]. Human primers
sequences and probes for Caspase-3, p53, BCLxs, death receptor-4 (DR-4), heme oxygenase-1 (HO-1),
NAD(P)H:quinone oxidoreductase-1 (NQO-1)and β-actin are illustrated in Table 1. These primers
were purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA).
Table 1. Primers sequences used for RT-PCR reactions.








2.7. Determination of Reactive Oxygen Species (ROS) Production
ROS was measured fluorometrically using 2,7-dichlorofluorescein diacetate (DCF-DA) assay as
described previously [24]. Briefly, MG63 cells were treated for 24 h with 10 µM DOX-Vit D. Thereafter,
cells were washed with PBS before incubated for 30 min in fresh media containing 10µM DCF-DA.
The fluorescence was directly measured using excitation and emission wavelengths of 485 and 535 nm,
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respectively, the Bio-Tek Synergy H1Hybrid Multi-Mode Microplate Readers (Bio-Tek Instruments,
Winooski, VT, USA).
2.8. Protein Extraction from MG63 Cells
MG63 cells were treated for 24 h with 10 µM DOX-Vit D or DOX, then the total cellular protein
was extracted from the cells as described previously [20].
2.9. Immuno Blot Analysis
Cell lysates were analyzed by SDS-PAGE and immunoblotting were performed as described
previously [20].
2.10. Determination of MAPKs Signaling Pathway
The protein phosphorylation of MAPKs was measured using the PhosphoTracer MAPK ELISA Kit
(Abcam, Cambridge, UK) according to manufacturer’s instructions and as described previously [20].
2.11. Extration of Nuclear Protein
MG63 cells were treated for 2 h with 10 µM DOX-Vit D or DOX, then the nuclear protein was
extracted from the cells as described previously [20,25].
2.12. Determination of NF-κB Binding Activity
The NF-κB binding activity was determined using NF-κB Assay Chemiluminescent Kit
(Millipore, Schwalbach/Ts., Germany, #70-660) according to the manufacturer’s protocol as described
previously [26].
2.13. Statistical Analysis
Results are shown as mean ± SEM. Statistical analysis was carried out using SigmaPlot® for
Windows (Systat Software, Inc., San Jose, CA, USA). One-way analysis of variance (ANOVA) followed
by Tukey-Kramer multiple comparison tests or unpaired two-sided student t-test was carried out.
A probability value obtained less than 0.05 is considered significant.
3. Results
3.1. Physiochemical Properities of DOX-Vit D in Comaprison to DOX
Given that the main purpose of the current study is to improve the lipopilicity of DOX, we
investigated the physiochemical properties of DOX-Vit D in comparison to DOX using ACD iLab
and VCCLAB software (https://www.acdlabs.com/resources/ilab/) as described previously [27].
Perhaps the better predictor of lipophilicity is the distribution coefficient at pH 7.4 (LogD7.4) since it
considers the ionizable group at certain pH in addition to the estimated partition coefficient (LogP).
Of interest, Table 2 shows that DOX-Vit D has clear higher predicted values of LogP and LogD7.4
in comparison to DOX. This was consistent with a low predicted water solubility of DOX-Vit D
(0.0029 µg/mL) in comparison to DOX (0.49 mg/mL) and a higher LogS value for DOX-Vit D.
Together, it is reasonable to assume that our novel DOX derivative, DOX-Vit D, is more lipophilic
than DOX.
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Table 2. Physicochemical properties of DoxVD vs. Dox and Vitamin D2.
Compound Doxorubicin (Free Base) Vitamin D2 DoxVD
Structure
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Chemical Formula C27H29NO11 C28H44O C59H75NO14
Molecular Weight
(g/mol) 543.53 396.65 1022.22
LogP (ACD Chemsketch) 2.82 ± 1.30 9.56 ± 0.27 12.83 ± 1.32
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3.2. Effect of DOX and DOX-Vit D on MG63 Cells Proliferation
To determine the cytotoxic effect of DOX and DOX-Vit D on OS, MG63 cells were exposed to
10 µM DOX and DOX-Vit D for 24 h. Thereafter, the cell proliferation was determined using MTT assay.
Our results showed that a 10 µM DOX did not significantly affect cell prolife ation at 24 h (Figure 3).
However, 10 µM DOX-Vit D significantly decreased the cell proliferation by approximately 50% in
comparison to control (Figure 3).
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Figure 3. Effect of DOX and DOX-Vit D on MG63 cells proliferation. MG63 cells were exposed to
10 µM DOX and DOX-Vit D for 24 h. Thereafter, the cell proliferation was determined using MTT assay.
The results are presented as the mean ± SEM (n = 6). + p < 0.05 compared to control.
3.3. Effect of DOX and DOX-Vit D on Proapoptotic Genes
To investigate whether the inhibitory effect of DOX-Vit D on MG63 cell proliferation and growth
is an apoptosis-dependent mechanism, MG63 cells were treated for 24 h with 10 µM DOX and DOX-Vit
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D. Thereafter, the mRNA levels of proapoptotic genes, Caspase-3, p53 and BCLxs, were determined by
real time-PCR. Figure 4 shows that DOX-Vit D caused a significant induction of Caspase-3 and BCLxs
genes expression by approximately 250% and 400%, respectively, in comparison to control. On the
other hand, DOX significantly decreased the expression of Caspase-3, BCLxs and P53 by about 50%,
20% and 30%, respectively, in comparison to control.
In light of our findings, DOX-Vit D seems to inhibit the growth of MG63 cells through an
apoptosis-dependent mechanism. Next, we questioned whether the DOX-Vit D elicited an apoptotic
signal in MG63 cells is mediated extrinsically through the activation of death receptor and/or
intrinsically by the induction of oxidative stress. Therefore, a series of independent experiments
were conducted as follows.
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Figure 4. Effect of DOX and DOX-Vit D on proapoptotic genes. MG63 cells were treated for 24 h with
10 µM DOX and DOX-Vit D. Thereafter, total RNA was isolated using TRIzol reagent, and the mRNA
levels of (A) Caspase-3, (B) p53 and (C) BCLxs were quantified using real time-PCR and normalized to
a β-actin housekeeping gene. The results are presented as the mean ± SEM (n = 6). + p < 0.05 compared
to control. * p < 0.05 compared to DOX.
3.4. Effect of DOX and DOX-Vit D on the Expression of DR-4
In order to determine the capacity of DOX and DOX-Vit D to modulate the expression of DR-4
mRNA, MG63 cells were treated for 24 h with 10 µM DOX and DOX-Vit D. Thereafter, the mRNA
levels of DR-4 was determined by real time-PCR. Figure 5 shows that treatment of MG63 cell with
DOX-Vit D caused a significant induction of DR-4 by about 170% in comparison to control. On the
other hand, DOX significantly inhibit the expression of DR-4 by approximately 60% in comparison
to control.
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3.5. Effect of DOX and DOX-Vit D on the Oxidative Stress
The involvement of intrinsic apoptotic pathway was addressed by two approaches. Firstly, we
determined the effect of DOX-Vit D and DOX on the mRNA expression of oxidative stress markers.
Figure 6 shows that treatment of cells with 10 µM DOX-Vit D caused a significant induction of NQO-1
and HO-1 by approximately 250% and 6000%, respectively, in comparison to control. In contrast, DOX
significantly inhibited the expression of HO-1 by about 70%, whereas no significant changes were
observed with NQO-1 (Figure 6A,B).
The second approach was to investigate the effect of DOX and DOX-Vit D on the generation of
ROS using DCF assay. The incubation of MG63 cells with DOX and DOX-Vit D for 24 h caused a
significant increase in the formation of ROS by about 400% and 350%, respectively, in comparison to
control (Figure 6C).
Our findings suggest an involvement of both extrinsic and intrinsic pathways in the induction
of proapoptotic genes by DOX-Vit D. The induction of the aforementioned pathways are known to
trigger apoptosis through the activation of MAPK signaling pathway. Thus, we have investigated
whether or not DOX-Vit D induces proapoptotic genes through MAPK signaling pathway.
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3.6. Effect of DOX and DOX-Vit D on MAPK Signaling Pathway
To assess the role of MAPK signaling pathway on the DOX-Vit D mediated induction of proapoptotic
genes, MG63 cells were treated with 10 µM DOX-Vit D and DOX. Thereafter, phosphorylated MAPK
levels were determined using a commercially available kit. Figure 7 shows that incubation of the cells with
10 µM of DOX-Vit D but not DOX significantly induced phosphorylation of p38 and JNK by approximately
250% and 160%, respectively, in comparison to control.
To further confirm whether activation of the MAPK pathways is required for the apoptotic cell
death mediated by DOX-Vit D, MG63 cells were treated with 10 µM p38 inhibitor, SB203580, and
JNK inhibitor, SP600125, in the presence and absence of DOX-Vit D. Thereafter, the cells proliferation
were measured using MTT assay. Figure 8 shows that DOX-Vit D alone caused a significant inhibition
of MG63 cell proliferation by about 50% in comparison to control. Importantly, treatment of cells
with SB203580 and SP600125 partially but significantly protects the cells against the cytotoxic effect of
DOX-Vit D. Our findings suggest that the activation of MAPK is essential for the cytotoxic effect of
DOX-Vit D.
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In order to examine whether the inhibitory effect of DOX-Vit D on MG63 cell proliferation and
growth is also attributed to the suppression of cell survival and proliferation pathways, we have
determined the effect of DOX-Vit D on NF-κB, Akt and mTOR signaling pathways.
3.7. Effect of DOX and DOX-Vit D on NF-κB Signaling Pathway
The basal activity of the NF-κB transcription factor in OS seems to be crucial for their growth or
resistance to chemotherapy. Therefore, we have investigated whether DOX-Vit D suppresses MG63 cell
growth through the inhibition of NF-κB. For this purpose, MG63 cells were treated with 10 µM DOX
and DOX-Vit D. Thereafter, NF-κB binding activity was determined using a commercially available kit.
Figure 9 shows that neither DOX nor DOX-Vit D significantly affects the binding activity of NF-κB
suggesting an NF-κB-independent mechanism.
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Figure 9. Effect of Effect of DOX and DOX-Vit D on NF-κB signaling pathway. MG63 cells were treated
for 24 h with 10 µM DOX and DOX-Vit D. Thereafter, NF-κB binding activity was determined in nuclear
extracts using a commercially available kit. The results are presented as the mean ± SEM (n = 6).
3.8. Effect of DOX and DOX-Vit D on Akt and mTOR Signaling Pathway
Since Akt and mTOR pathway promotes cell growth, proliferation and survival, we examined
the effect of DOX-Vit D on Akt and mTOR signaling pathway. For this purpose, MG63 cells were
treated with 10 µM DOX and DOX-Vit D. Thereafter, Akt and mTOR protein expression levels were
determined using Western blot analysis. Figure 10 shows that DOX-Vit D caused a significant inhibition
of p-Akt and p-mTOR protein expression by approximately 40% and 50%, respectively, in comparison
to control suggesting an Akt/mTOR-dependent inhibition of cell growth by DOX-Vit D. In contrast,
DOX did not significantly alter the expression of p-Akt and p-mTOR protein expression.
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4. Discus ion
These investigations provide strong evidence that DOX-Vit D suppresses the growth of uman OS,
MG63 cell line, through the induction of apoptosis and the inhibition of cell survival and proliferative
signaling pathways.
One of the strategies for treating OS and minimizing the development of chemoresistance
associated with chemotherapeutic agents includes the induction of apoptosis and/or the attenuation
of cell survival and proliferative signaling pathways. Studies using transgenic mice provide direct
evidence that overexpression of cell survival pathways and/or disruption of apoptosis promote
tumorigenesis, metastasis and contribute to chemoresistance [28,29]. Therefore, the development of a
new chemotherapeutic agent that is able to attenuate the proliferation of OS while inducing apoptosis
is an urgently eeded to overcome chemoresistance.
DOX, a broad-spectrum anthracycline antibiotic, is one of those standard therapies for the
treatment f [5]. Unfortunately, the effectiveness of DOX in OS is usually limited by the
acq ired drug resistance that leads to po r prognosis and sub ptimal outcomes [30]. Recently, Vit-D
has been shown to suppress the growt of many human cancer cells and reverse chemotherapy
drug-resistant [30,31]. Taken together, we synthesized DOX-Vit D by conjugati g Vit-D to DOX
in order to mitigate the chemoresistance associated with DOX. The current study was conducted
to investigate the antipr liferative and apoptogenic effects of 10 µM DOX-Vit D in comparison to
10 µM DOX and the possible mechanism(s) involved usi g the human OS cell line, MG63 cells.
The concentration of DOX used in the current study was maintained within the therapeutic range f
plasma concentration reported in human. For example, human subjects given a dose of 60–75 mg/m2
DOX for the treatment of etastatic cancer had mean plasma concentrations range from 5 and 15 µM
and an average half-life of ∼25 h [32,33]. In addition, several in vitro studies on human cancer cells to
explore the cytotoxicity of DOX used concentrations range from 1 to 10 µM [32,33].
Initially, we have demonstrated that DOX-Vit D, but not DOX, was able to significantly suppress
the MG63 cell proliferation and growth. Notably, the anticancer effect of DOX-Vit D is attributed to the
induction of proa optotic genes Caspase-3 and BCLxs. Activation of the proapo totic genes plays a
crucial role in the initiation of apo tosis through the cleavage of the key cellular proteins resulting in
the irreversible commit ent to cell death [29,34]. Similar to our observation, it has been reported that
calciferol and its chemical derivative, MT19c, induce apoptosis and inhibit the growth and proliferation
of many cancer cell lines through the activation of the Caspase-3 enzyme [35,36]. The inhibitory effect
of DOX on proapoptotic genes might be attributed to the fact that our MG-63 cells are resistant to
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DOX. In agreement with our results, it has been shown that 10 µM DOX was neither elicit Caspase-3
activation or apoptosis in DOX resistant MG63 cells [37]. Importantly, promoting apoptosis has been
shown to overcome the chemoresistance associated with DOX during the treatment of OS [38].
Apoptosis is known to be elicited by the activation of extrinsic and/or intrinsic signals.
These signals are instructing the cells to undergo programmed cell death through the activation of
proapoptotic genes [29,34]. Accordingly, we investigated whether the DOX-Vit D-induced apoptosis in
MG63 cells is mediated through the extrinsic and/or intrinsic apoptotic pathway. The extrinsic signals
induce apoptosis through binding of cell surface death receptors such as TNF/Fas-receptor with its
ligand and subsequently activates proapoptotic enzymes [39]. Hence, we have tested whether DOX-Vit
D triggers extrinsic apoptotic pathway by measuring the expression of DR-4. In this current study,
we found that the induction of DR-4 mRNA in response to DOX-Vit D significantly contributes to the
activation of proapoptotic genes. These findings are in agreement with the observation that calciferol
increases the activity of proapoptotic genes through the induction of DR [36]. On the other hand, DOX
seems to decrease the expression of proapoptotic genes through the downregulation of DR-4.
The intrinsic signal is another pivotal pathway that could initiate apoptosis through the oxidative
stress and ROS-dependent mechanism [40]. Oxidative stress and ROS have been considered as a potent
inducer of apoptosis [41]. In this context, the involvement of the intrinsic apoptotic pathway in the
cytotoxic effect of DOX-Vit D was evidenced by the induction of the oxidative stress markers, NQO-1
and HO-1, in addition to the generation of ROS. In a manner similar to our observations, it has been
reported that calciferol treatment results in the accumulation of ROS and subsequently coordinates
proapoptotic genes activation [36].
Our findings suggest that DOX-Vit D upregulated the expression of proapoptotic genes through
the activation of both extrinsic and intrinsic apoptotic pathways. The induction of the aforementioned
pathways are known to trigger apoptosis through the activation of the MAPK signaling pathway.
A wealth of information suggests the involvement of MAPK cascades in cell death and survival
signaling [42,43]. In particular, it has demonstrated that persistent activation of p38 and JNK promotes
apoptosis and cell death [42,43]. Taken together, the possibility that DOX-Vit D would induce apoptosis
through the activation of MAPKs could not be ruled out. Thus, the third objective of the current study
was to explore the role of DOX-Vit D on the MAPKs signaling pathway. Our results demonstrate
that DOX-Vit D, but not DOX, significantly increased the protein expression level of p-p38 and p-JNK
whereas no significant changes were observed on p-ERK1/2. The direct evidence for the involvement of
p-p38 and p-JNK in the DOX-Vit D-induced cytotoxicity was supported by the observation that p-p38
inhibitor, SB203580, and JNK inhibitor, SP600125, significantly protect against DOX-Vit D-induced
cell death suggesting a MAPK-dependent mechanism. The premise of this observation emerges
from the finding that calciferol chemical derivative, MT19c, induces apoptosis through a p38 and
JNK-dependent mechanism [35].
Apoptosis-mediated cell death might induce the turn off of survival pathways, such as NF-κB
and Akt/mTOR pathways, that could otherwise interfere with the apoptotic response. The aberrant
activation of those proliferating proteins in OS seems to be crucial for their growth or resistance
to chemotherapy [44,45]. Thus, it is imperative to investigate the effect of DOX-Vit D on the
aforementioned cell survival and proliferating pathways. Although DOX-Vit D did not significantly
affect the binding activity level of NF-κB in MG63 cells, DOX-Vit D significantly downregulated
the protein expression level of p-Akt and p-mTOR. In addition, DOX did not significantly alter
the p-Akt/p-mTOR proteins expression. These results are in agreement with previous reports
on OS showing that high Akt/mTOR activity was associated with poor clinical outcome and
chemoresistence associated with DOX [46,47]. On the other hand, everolimus, an mTOR inhibitor,
has been shown to decrease drug-induced resistance in OS [48,49]. Our findings not only suggest an
Akt/mTOR-dependent inhibition of MG63 cell growth by DOX-Vit D but also support DOX-Vit D as a
promising developmental strategy for the treatment of OS resistant to chemotherapy [50].
Pharmaceutics 2018, 10, 144 14 of 16
To reiterate, our results clearly demonstrated that DOX-Vit D, a novel DOX derivative, suppresses
MG63 cell growth through the induction of apoptosis and the inhibition of Akt/mTOR signaling
pathways. Such observation will raise the potential of developing DOX-Vit D analogues for the
treatment of OS resistant to chemotherapy. Given that DOX-VitD has a higher lipophilicity compared
to DOX, it is reasonable to assume that DOX-VitD may serve as a novel drug delivery approach to
minimize the first-pass effect while increasing lymphatic exposure and ultimately improving overall
systemic drug exposure. Additional studies are going to test the toxicity and the kinetic of DOX-VitD
in rats. Our preliminary data have shown that DOX-VitD is tolerable upon oral and intravenous
administration in rats. Given that our new derivative has a stoichiometry of 1 to 1 ratio (Dox-VitD), it
might not necessarily be the most active one. Therefore, we will compare our new derivative with a
combination of the free drugs at different ratios in order to confirm the mechanism(s) of action and
discriminate additive effects vs synergistic effects.
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